Overcoming aspirin treatment failure in diabetes

Critical Reviews in Clinical Laboratory Sciences

Volumn 49, Issue 5-6, 2012, Pages 183-198

  Linden, Matthew D ^a,b   Tran, Huyen A ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b RMIT UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Antiplatelet therapy; Aspirin resistance; Atherothrombosis; Cardiovascular disease; Guided therapy; High on treatment platelet reactivity; Platelet hyper reactivity

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ATOPAXAR; CLOPIDOGREL; CYCLOOXYGENASE 1; DICLOFENAC; IBUPROFEN; INSULIN; KETOPROFEN; KETOROLAC; METFORMIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; THROMBOXANE; THROMBOXANE B2; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANALYTICAL EQUIPMENT; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIET; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EXERCISE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT RESPONSE;

ASPIRIN; CYCLOOXYGENASE 1; DIABETES MELLITUS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TREATMENT FAILURE;

EID: 84871195810     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2012.731377     Document Type: Review

References (221)

1. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694-2701.
2. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
3. Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes 1989;38:350-357.
4. Balasubramaniam K, Viswanathan GN, Marshall SM, Zaman AG. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract 2012;2012:909154.
5. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-942.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
7. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126.
8. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 2007;28:1925-1927.
9. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-390.
10. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
11. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Br Med J 2009;339:b4531.
12. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
13. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl6):199S-233S.
14. Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012;38:200-212.
15. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008;6:2035-2044.
16. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311.
17. Linden MD, Frelinger AL III, Przyklenk K, Furman MI, Michelson AD. Aspirin resistance: detection, mechanisms, and clinical implications. Curr Cardiol Rev 2005;1:203-212.
18. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-2596.
19. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
20. Eikelboom J, Feldman M, Mehta SR, Michelson AD, Oates JA, Topol E. Aspirin resistance and its implications in clinical practice. Med Gen Med 2005;7:76.
21. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008;336:195-198.
22. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
23. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
24. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. J Am Med Assoc 2009;302:849-857.
25. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-1934.
26. Holmes DR K.P., Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537-557.
27. Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006;113:2888-2896.
28. Cuisset T, Frere C, Quilici J, Gaborit B, Bali L, Poyet R, et al. Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J 2009;157:889-893.
29. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains Interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220-1230.
30. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-435.
31. Petricevic M, Biocina B, Konosic S, Ivancan V. Impact of aspirin resistance on antiplatelet therapy management after coronary artery surgery. Eur J Cardiothorac Surg 2012.
32. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 2010;9:154-169.
33. Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, et al. Feasibility of conducting a primary prevention trial of lowdose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008;189:105-109.
34. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.
35. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30:74-77.
36. U.S. Census of Population and Housing, 2010. Washington: Government Printing Office; 2011. Available at http://www. census.gov/prod/cen2010. Accessed on 14 September 2012.
37. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-593.
38. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
39. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:405-410.
40. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396-404.
41. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13 (Suppl 1):1-68.
42. Bhattacharyya OK, Shah BR, Booth GL. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ 2008;179:920-926.
43. Standards of medical care in diabetes-2012. Diabetes Care 2012;35 (Suppl 1):S11-S63.
44. Davi G, Vazzana N, Sestili S. Variability in the response to antiplatelet treatment in diabetes mellitus. Prostaglandins Other Lipid Mediat 2012;98:48-55.
45. Bloomgarden ZT. Diabetes and cardiovascular disease. Diabetes Care 2011;34:e24-e30.
46. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J 2008;337:a1840.
47. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. J Am Med Assoc 2008;300:2134-2141.
48. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796-1801.
49. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009;23:375-388.
50. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531-540.
51. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
52. Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 2009;405:8-16.
53. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010;48:579-598.
54. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
55. Linden MD, Frelinger AL 3rd, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004;30:501-511.
56. Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349-354.
57. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011;97:983-990.
58. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336.
59. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113:31-35.
60. Zhang Y, Liang J, Zhou YJ, Yuan H, Zhang YZ, Dong L. Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi 2005;33:695-699.
61. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol 2006;98:4N-10N.
62. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007;28:1673-1675.
63. Poston RS, Gu J, Brown JM, Gammie JS, White C, Nie L, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006;131:122-130.
64. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
65. Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761-765.
66. Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006;35:67-82.
67. Krueger LA, Barnard MR, Frelinger AL 3rd, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. Curr Protoc Cytom 2002;Chapter 6:Unit 6.10.
68. Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM. Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000;16:1385-1390.
69. Santilli F, Romano M, Recchiuti A, Dragani A, Falco A, Lessiani G, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 2008;112:1085-1090.
70. Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, et al. The contribution of cyclooxygenase-1 and-2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood 2010;115:1054-1061.
71. Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Pinca E, Satta MA, et al. Evidence for a renal origin of urinary thromboxane B2 in health and disease. Adv Prostaglandin Thromboxane Leukot Res 1983;11:493-498.
72. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987;47:647-656.
73. Chen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005;96:760-763.
74. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-1126.
75. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:1492-1494.
76. Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005;3:10.
77. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66.
78. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005;207:59-64.
79. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269-280.
80. Yilmaz MB, Balbay Y, Caldir V, Ayaz S, Guray Y, Guray U, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005;115:25-29.
81. Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, Koylan N, et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007;18:461-465.
82. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49.
83. Anderson KE, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thrombosis Res 2002;108:37-42.
84. Golanski J, Nocun M, Rozalski M, Drygas W, Watala C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis 2004;15:187-195.
85. Michelson AD, Frelinger AL III, Furman MI. Resistance to antiplatelet drugs. Eur Heart J 2006;8:G53-G58.
86. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-1713.
87. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010;8:2140-2148.
88. Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526-536.
89. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011;9:185-191.
90. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010;126:e318-e322.
91. Mori TA, Vandongen R, Douglas AJ, McCulloch RK, Burke V. Differential effect of aspirin on platelet aggregation in IDDM. Diabetes 1992;41:261-266.
92. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103.
93. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986;68:886-891.
94. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014-3019.
95. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004;113:101-113.
96. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 2006;97:38-43.
97. Gresele P, Marzotti S, Guglielmini G, Momi S, Giannini S, Minuz P, et al. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010;33:1262-1268.
98. Lemkes BA, Bahler L, Kamphuisen PW, Stroobants AK, Van Den Dool EJ, Hoekstra JB, et al. The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. J Thromb Haemost 2012;10:639-646.
99. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004;21:793-811.
100. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999;17:1041-1045.
101. Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians' Health Study. Arch Intern Med 1994;154:2649-2657.
102. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293-300.
103. Ferreira-Gonzalez I, Marsal JR, Ribera A, Permanyer-Miralda G, Garcia-Del Blanco B, Marti G, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010;122:1017-1025.
104. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973-975.
105. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008;6:46.
106. Cuisset T, Quilici J, Fugon L, Cohen W, Roux P, Gaborit B, et al. Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. Arch Cardiovasc Dis 2011;104:306-312.
107. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667-2674.
108. Lordkipanidze M, Diodati JG, Pharand C. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence. Pharmacol Ther 2009;123:178-186.
109. Lordkipanidze M, Harrison P. Beware of being caught on the rebound. J Thromb Haemost 2011;9:21-23.
110. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2010;96:368-371.
111. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258-1263.
112. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:2153-2158.
113. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. Br Med J 2011;342:d2690.
114. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging 2006;23:559-567.
115. Kubacka RT, Antal EJ, Juhl RP, Welshman IR. Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother 1996;30:20-26.
116. Chang J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis and its impact on glycemia. Endocrinol Metab Clin North Am 2010;39:745-762.
117. Hasler WL, Coleski R, Chey WD, Koch KL, McCallum RW, Wo JM, et al. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol 2008;294:G1384-G1391.
118. Stacher G. Diabetes mellitus and the stomach. Diabetologia 2001;44:1080-1093.
119. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39:215-231.
120. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003;27:907-911.
121. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 2008;22:224-228.
122. Ertugrul DT, Tutal E, Yildiz M, Akin O, Yalcin AA, Ure OS, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:2897-2901.
123. Dyken ML, Barnett HJ, Easton JD, Fields WS, Fuster V, Hachinski V, et al. Low-dose aspirin and stroke. "It ain't necessarily so". Stroke 1992;23:1395-1399.
124. Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs 2004;4:151-158.
125. Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? Thromb Res 1998;92:S7-12.
126. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774.
127. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010;8:828-837.
128. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279-1286.
129. Di Minno G. Aspirin resistance and platelet turnover: A 25-year old issue. Nutr Metab Cardiovasc Dis 2011;21:542-545.
130. Guthikonda S, Lev EI, Patel R, DeLao T, Bergeron AL, Dong JF, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007;5:490-496.
131. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
132. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743-749.
133. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008;99:930-935.
134. Hekimsoy Z, Payzin B, Ornek T, Kandogan G. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004;18:173-176.
135. Watala C, Boncler M, Pietrucha T, Trojanowski Z. Possible mechanisms of the altered platelet volume distribution in type 2 diabetes: does increased platelet activation contribute to platelet size heterogeneity? Platelets 1999;10:52-60.
136. Vaduganathan M, Alviar CL, Arikan ME, Tellez A, Guthikonda S, DeLao T, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 2008;156:1002. e1-1002. e7.
137. Mackenzie IS, Coughtrie MW, MacDonald TM, Wei L. Antiplatelet drug interactions. J Intern Med 2010;268:516-529.
138. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
139. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003;108:1191-1195.
140. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-574.
141. Umar A, Boisseau M, Yusup A, Upur H, Begaud B, Moore N. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam Clin Pharmacol 2004;18:559-563.
142. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-489.
143. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004;44:140-145.
144. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001;286:954-959.
145. Vignini A, Moroni C, Nanetti L, Raffaelli F, Cester A, Gabrielli O, et al. Alterations of platelet biochemical and functional properties in newly diagnosed type 1 diabetes: a role in cardiovascular risk? Diabetes Metab Res Rev 2011;27:277-285.
146. Caimi G, Canino B, Montana M, Catania A, Lo Presti R. Platelet membrane fluidity in non-insulin-dependent diabetes mellitus (NIDDM) subjects, in subjects with vascular atherosclerotic disease (VAD) and in VAD subjects with NIDDM. Thromb Haemost 1999;82:149.
147. Watala C, Boncer M, Golanski J, Koziolkiewcz W, Trojanowski Z, Walkowiak B. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. Eur J Haematol 1998;61:319-326.
148. Ames PR, Batuca JR, Muncy IJ, De La Torre IG, Pascoe-Gonzales S, Guyer K, et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. Thromb Res 2012;130:350-354.
149. Liani R, Halvorsen B, Sestili S, Handberg A, Santilli F, Vazzana N, et al. Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. Free Radic Biol Med 2012;52:1318-1324.
150. Davi G, Averna M, Catalano I, Barbagallo CM, Giovenco E, Carroccio A, et al. Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic control. Diabetes Res 1989;10:7-12.
151. Halushka PV, Rogers RC, Loadholt CB, Colwell JA. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 1981;97:87-96.
152. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004;34:205-209.
153. Tarnow I, Michelson AD, Barnard MR, Frelinger AL 3rd, Aasted B, Jensen BR, et al. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets 2009;20:513-519.
154. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-2188.
155. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004;47:537-540.
156. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997;29:631-635.
157. Kaplar M, Kappelmayer J, Veszpremi A, Szabo K, Udvardy M. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets 2001;12:419-422.
158. Hu H, Li N, Yngen M, Ostenson CG, Wallen NH, Hjemdahl P. Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2004;2:58-64.
159. Ford I, Singh TP, Kitchen S, Makris M, Ward JD, Preston FE. Activation of coagulation in diabetes mellitus in relation to the presence of vascular complications. Diabet Med 1991;8:322-329.
160. Takeda H, Maeda H, Fukushima H, Nakamura N, Uzawa H. Increased platelet phospholipase activity in diabetic subjects. Thromb Res 1981;24:131-141.
161. Matsuda T, Morishita E, Jokaji H, Asakura H, Saito M, Yoshida T, et al. Mechanism on disorders of coagulation and fibrinolysis in diabetes. Diabetes 1996;45 (Suppl 3):S109-S110.
162. Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV. High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. J Thromb Haemost 2007;5:1562-1564.
163. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813.
164. Ueno M, Ferreiro JL, Tomasello SD, Capodanno D, Tello-Montoliu A, Kodali M, et al. Functional profile of the platelet P2Y(1)(2) receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost 2011;105:730-732.
165. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001;280:H1480-H1489.
166. Yamaguchi T, Kadono K, Tetsutani T, Yasunaga K. Platelet free Ca2+ concentration in non-insulin-dependent diabetes mellitus. Diabetes Res 1991;18:89-94.
167. Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation 2006;113:2865-2867.
168. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.
169. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
170. Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events Study. Circulation 2012;125:3201-3210.
171. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
172. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
173. Faraday N, Becker DM, Yanek LR, Herrera-Galeano JE, Segal JB, Moy TF, et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006;98:774-779.
174. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL 3rd, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004;43:2319-2325.
175. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-886.
176. O'Sullivan BP, Linden MD, Frelinger AL 3rd, Barnard MR, Spencer-Manzon M, Morris JE, et al. Platelet activation in cystic fibrosis. Blood 2005;105:4635-4641.
177. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002;14:51-58.
178. Censarek P, Freidel K, Udelhoven M, Ku SJ, Hohlfeld T, Meyer-Kirchrath J, et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004;92:925-928.
179. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
180. Schuster VL. Molecular mechanisms of prostaglandin transport. Annu Rev Physiol 1998;60:221-242.
181. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998;79:691-705.
182. Patrono C, Falco A, Davi G. Isoprostane formation and inhibition in atherothrombosis. Curr Opin Pharmacol 2005;5:198-203.
183. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets 2011;22:188-195.
184. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002;287:2570-2581.
185. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004;109:2524-2528.
186. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004;25:166-181.
187. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001;103:3051-3056.
188. Pettinella C, Romano M, Stuppia L, Santilli F, Liani R, Davi G. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009;101:687-690.
189. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res 2011;128:47-53.
190. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597-1602.
191. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-130.
192. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008;66:222-232.
193. Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet 2009;75:1-18.
194. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008;118:1705-1712.
195. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
196. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol 2006;60:144-151.
197. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005;149:832-839.
198. Fusegawa Y, Goto S, Handa S, Kawada T, Ando Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res 1999;93:271-278.
199. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 2005;112:1024-1029.
200. Lordkipanidze M, Harrison P. Aspirin twice a day keeps new COX-1 at bay. J Thromb Haemost 2012;10:1217-1219.
201. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-1243.
202. Persell SD, Baker DW. Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 2004;164:2492-2499.
203. Miller SR, Littenberg B, MacLean CD. Prevalence of antiplatelet therapy in patients with diabetes. Cardiovasc Diabetol 2005;4:18.
204. von Pape KW, Strupp G, Bonzel T, Bohner J. Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction. Thromb Haemost 2005;94:889-891.
205. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-1301.
206. Saxena A, Weber H, Schror K, Hohlfeld T. Remarkable differences in the effect of individual nonsteroidal anti-inflammatory drugs on the antiplatelet action of aspirin. Circulation 2011;124:A10243.
207. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
208. Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999;353:2179-2184.
209. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991;325:1261-1266.
210. Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am 1985;67:57-62.
211. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): a randomised factorial trial. Lancet 2010;376:1233-1243.
212. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-942.
213. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
214. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805.
215. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011;32:1854-1864.
216. Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol 2011;150:39-44.
217. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180-187.
218. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro-or macrovascular complications. Thromb Haemost 2011;106:491-499.
219. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin nonresponders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 2004;38:353-356.
220. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, Michelson AD, Jakubowski JA, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838-846.
221. Sharma RK, Voelker DJ, Sharma R, Reddy HK, Dod H, Marsh JD. Evolving role of platelet function testing in coronary artery interventions. Vasc Health Risk Manag 2012;8:65.